Ongoing Clinical Trials for Bladder Transitional Cell Carcinoma Recurrent
This article provides information about ongoing clinical trials for patients with recurrent bladder transitional cell carcinoma. Currently, there is 1 active trial investigating new surgical approaches to reduce the need for repeat procedures and improve outcomes for patients with non-muscle invasive bladder cancer.
Clinical trial locations
Study on Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer to Reduce Need for Second Surgery
This clinical trial is investigating whether a special surgical technique can help patients with non-muscle invasive bladder cancer avoid the need for a second surgery. The study is taking place in Italy and focuses on comparing two different methods for removing bladder tumors.
Main inclusion criteria:
- Adults aged 18 years or older, both male and female
- Clinical suspicion of primary or recurrent bladder cancer requiring TURBT (trans-urethral resection of bladder tumor)
- Confirmed diagnosis of non-muscle invasive bladder cancer, including CIS, Ta, T1, N0, and M0 types
- Candidates for a second look and resection according to European guidelines
- No previous BCG immunotherapy treatment
- Ability to undergo all study procedures and provide informed consent
Main exclusion criteria:
- Patients with other types of bladder cancer that are not non-muscle invasive
- Patients outside the specified age range
- Vulnerable populations requiring special protection
- Patients not meeting other specific health requirements
Study focus and goals:
The trial compares two surgical approaches for removing bladder tumors. The first method uses Photodynamic Trans-urethral Resection of Bladder Tumors (PDD-TURBT), which involves a light-sensitive drug called Hexvix (hexaminolevulinate) that helps doctors see cancerous tissue more clearly during surgery. The second method is the conventional approach using white light during surgery, followed by a second surgery if needed.
The main goal is to determine whether the PDD-TURBT method can effectively eliminate the need for a second surgery without increasing the risk of cancer returning. Patients will be randomly assigned to one of the two surgical methods and monitored carefully over several months with scheduled follow-up appointments.
After the initial procedure, patients will have their first follow-up cystoscopy at 3 months to check for early recurrence. Additional follow-ups occur at 4.5 months to monitor for late recurrences and disease progression. The trial is expected to conclude by July 31, 2027.
Investigational treatment:
The study uses Hexvix (hexaminolevulinate), a light-sensitive medication administered directly into the bladder before surgery. When exposed to a special light during the procedure, this drug causes cancerous tissues to glow, making them easier for surgeons to identify and remove completely. This photodynamic approach works at the molecular level by producing reactive oxygen species that damage and destroy cancer cells when activated by light.
Throughout the study, researchers will evaluate how often cancer returns, the time it takes for any recurrence, the overall health and quality of life of participants, and the costs associated with each method. The findings could help improve treatment guidelines for patients with non-muscle invasive bladder cancer.
Summary
Currently, there is one ongoing clinical trial for patients with recurrent bladder transitional cell carcinoma, located in Italy. This trial focuses on an innovative surgical approach using photodynamic diagnosis to enhance tumor visualization during removal procedures. The study aims to determine whether this technique can reduce the need for repeat surgeries while maintaining effective cancer control. The trial represents an important step in exploring less invasive treatment options for patients with non-muscle invasive bladder cancer.